# Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

> **NCT01598051** · — · COMPLETED · sponsor: **Bayer** · enrollment: 741 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation (NVAF)

## Interventions

- **DRUG:** Rivaroxaban (Xarelto_ BAY59-7939)

## Key facts

- **NCT ID:** NCT01598051
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-31
- **Primary completion:** 2016-06-09
- **Final completion:** 2017-03-31
- **Target enrollment:** 741 (ACTUAL)
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01598051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01598051, "Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01598051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*